Detailed Information

Cited 5 time in webofscience Cited 5 time in scopus
Metadata Downloads

Chemical genetics-based development of small molecules targeting hepatitis C virus

Authors
Jin, GuanghaiLee, JisuLee, Kyeong
Issue Date
Sep-2017
Publisher
PHARMACEUTICAL SOC KOREA
Keywords
Hepatitis C virus; Chemical genetics; Drug discovery
Citation
ARCHIVES OF PHARMACAL RESEARCH, v.40, no.9, pp 1021 - 1036
Pages
16
Indexed
SCIE
SCOPUS
KCI
Journal Title
ARCHIVES OF PHARMACAL RESEARCH
Volume
40
Number
9
Start Page
1021
End Page
1036
URI
https://scholarworks.dongguk.edu/handle/sw.dongguk/23307
DOI
10.1007/s12272-017-0949-3
ISSN
0253-6269
1976-3786
Abstract
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFN alpha with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFN alpha and RBV with either the first-generation DAAs boceprevir or telaprevir. In the past several years, various novel small molecules have been discovered and some of them (i.e., HCV polymerase, protease, helicase and entry inhibitors) have undergone clinical trials. Between 2013 and 2016, the second-generation DAA drugs simeprevir, asunaprevir, daclatasvir, dasabuvir, sofosbuvir, and elbasvir were approved, as well as the combinational drugs Harvoni(A (R)), Zepatier(A (R)), Technivie(A (R)), and Epclusa(A (R)). A number of reviews have been recently published describing the structure-activity relationship (SAR) in the development of HCV inhibitors and outlining current therapeutic approaches to hepatitis C infection. Target identification involves studying a drug's mechanism of action (MOA), and a variety of target identification methods have been developed in the past few years. Chemical biology has emerged as a powerful tool for studying biological processes using small molecules. The use of chemical genetic methods is a valuable strategy for studying the molecular mechanisms of the viral lifecycle and screening for anti-viral agents. Two general screening approaches have been employed: forward and reverse chemical genetics. This review reveals information on the small molecules in HCV drug discovery by using chemical genetics for targeting the HCV protein and describes successful examples of targets identified with these methods.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Pharmacy > Department of Pharmacy > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Kyeong photo

Lee, Kyeong
College of Pharmacy (Department of Pharmacy)
Read more

Altmetrics

Total Views & Downloads

BROWSE